Pre-emptive Cycline Treatment on Cetuximab Induced Skin Toxicity in Colorectal Cancer

Overview

The aim of this study is to test the role of cycline in the prevention of acne-like skin rash in metastatic colorectal patients treated with Cetuximab and intensified FOLFIRI.

Full Title of Study: “Pre-emptive Cycline Treatment on Cetuximab-induced Skin Toxicity in Patients With Metastatic Colorectal Cancer Treated With an Intensified FOLFIRI.”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: October 10, 2016

Detailed Description

Cetuximab, an Epidermal Growth Factor Receptor (EGFR) inhibitor, has shown to improve FOLFIRI efficacy up to 59.3% OR, in wild KRAS patients with advanced colorectal cancer. Skin toxicity occurs in 81.6% of patients as an acne-like skin rash developed on the face and the trunk inducing pain, decreasing quality of life and drug compliance. Over 104 patients enrolled in a phase II clinical trial sponsored by Center Paul Papin (NCT 00 559741), a grade > or = 2 cetuximab-acneiform rash occured in 51 patients (49%). In this trial Cetuximab was combined with a FOLFIRI intensified (5-FU intensification based on pharmacokinetics and pharmacogenetic studies of UGT1A1 status and DPD). Until now, no pre-emptive skin toxicity treatment with cycline has been demonstrated. Because of cycline's anti inflammatory properties and their use in inflammatory acne, cycline could prevent cetuximab-induced skin rash. In a randomized double-blind placebo-controlled phase III trial, Jatoi et al., failed to highlight any cycline effect on 61 patients. On the other hand, the STEPP study (95 pts) showed the impact of cycline to prevent panitumumab related skin toxicities. Our primary objective is to reduce the incidence of grade > or = 2 acne-like skin rash by 30% with a 6 weeks pre-emptive cycline treatment in patients with metastatic colorectal cancer undergoing cetuximab therapy.

Interventions

  • Drug: Doxycycline
    • Doxycycline 100 mg daily per os to start 7 days before Cetuximab for 6 weeks.
  • Drug: Cetuximab
    • 500 mg/m² IV infusion of 60 minutes every 15 days

Arms, Groups and Cohorts

  • Experimental: Arm A
    • Intensified FOLFIRI plus Cetuximab + Doxycycline 100 mg daily per os to start 7 days before Cetuximab for 6 weeks + skin moisturizers (Dexeryl), sun protection.
  • Active Comparator: Arm B
    • Intensified FOLFIRI plus Cetuximab + skin moisturizers (Dexeryl), sun protection.

Clinical Trial Outcome Measures

Primary Measures

  • reduction of Grade > or = 2 acne-like skin rash by 30%
    • Time Frame: 6 weeks of pre-emptive cycline treatment
    • Skin tolerance will be assessed by a dermatologist at each cycle and NCI CTCAE v4.0 will be use for grading. Skin standardized photographs will be done at every cycle and a central double blind review wil be planned. Time to first occurence of grade > or =2 skin toxicity will be assessed, and specificity.

Secondary Measures

  • skin tolerance assessment
    • Time Frame: Until the end of Cetuximab treatment
    • Skin tolerance will be assessed weekly by a dermatologist from C1 to C3, and biweekly from C4 to C6 and NCI CTCAE v4.0 will be use for grading. All grade > or = 1 skin and hair/nails toxicities will be reported. Time to most severe skin toxicity will be assessed. Quality of life questionnaires with a skin interest (DLQI) will be evaluated at baseline and at each cycle.
  • Non skin toxicities assessment
    • Time Frame: Until the end of chemotherapy treatment
    • For non skin toxicities, only grade > or = 3 will be reported.
  • Efficacy Objective Response (OR) assessment
    • Time Frame: Until the end of chemotherapy treatment
    • Efficacy OR (Complete Response + Partial Response) will be assessed by the investigator with usual tumoral evaluation. Tumoral evaluation will be assessed with the same exam throughout the trial.
  • Biological correlation with response and survival
    • Time Frame: 3 years
    • Biological correlation with response and survival will be tested for KRAS, BRAF, PI3K,PTEN, epiregulin, amphiregulin, IGF1, Syndecan-1, UBE2C, EGFR polymorphism.
  • Time To Progression and Overall Survival
    • Time Frame: 3 years
  • Resectability rate
    • Time Frame: Until the end of chemotherapy treatment

Participating in This Clinical Trial

Inclusion Criteria

  • Advanced or metastatic colorectal cancer, histologically confirmed, first or second metastatic line – K-RAS wild-type – Adjuvant prior chemotherapy allowed provided that all toxicities are grade < or = 1 (excepted alopecia and neuropathy) – Age between 18 and 80 years – WHO Performance Status < or = 2 – Complete initial assessment before first treatment administration for imaging and pharmacogenetic, within 15 days for biology, and within 7 days for clinical examination. – Haematologic and hepatic parameters : neutrophils > or = 1500 /mm3, platelets > or = 100000/mm3, Total bilirubin < or 2 x ULN, AST and ALT < or = 3 x ULN, APL < or = 5 x ULN – Absence of total dihydropyrimidine dehydrogenase deficiency – Patient able to comply with study requirements – Signed written informed consent Exclusion Criteria:

  • History or presence of an other cancer, excepted cutaneous cancer (basocellular carcinoma), in situ cancer of the cervix or breast cancer curatively treated – Any other concomitant anti-cancer therapy – Prior anti EGFR therapy, anti angiogenic therapy is allowed – Prior cyclines hypersensitivity – Treatment with cyclines within 7 days before randomization – Presence of a rash at randomization time – Symptomatic or uncontrolled ventral nervous system metastases – Total dihydropyrimidine dehydrogenase deficiency – No recovery of any toxicity Grade < or = 1 related to a past anticancerous treatment excepted for alopecia and neuropathy – Active inflammatory bowel disease or other bowel – Significant serious pathology or any unstable medical condition (cardiac pathology uncontrolled, myocardial infarction within 6 months before enrollment, systemic active uncontrolled infection) – atropine contra-indication – any investigational agent without marketing authorization within 4 weeks before enrollment – Patient who is pregnant or breast feeding – Woman or man of childbearing potential not consenting to use adequate contraceptive precautions during the study

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 80 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Institut Cancerologie de l’Ouest
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Olivier Capitain, MD, PhD, Principal Investigator, Institut Cancerologie de l’Ouest

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.